28,060 Shares in UiPath Inc. (NYSE:PATH) Purchased by Titleist Asset Management LLC

Titleist Asset Management LLC acquired a new position in shares of UiPath Inc. (NYSE:PATH) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 28,060 shares of the healthcare company’s stock, valued at approximately $493,000.

Several other institutional investors and hedge funds also recently bought and sold shares of PATH. JPMorgan Chase & Co. increased its position in UiPath by 127.6% during the first quarter. JPMorgan Chase & Co. now owns 797,003 shares of the healthcare company’s stock worth $13,995,000 after buying an additional 446,751 shares during the last quarter. Rockefeller Capital Management L.P. increased its stake in shares of UiPath by 531.2% in the first quarter. Rockefeller Capital Management L.P. now owns 20,741 shares of the healthcare company’s stock worth $364,000 after purchasing an additional 17,455 shares during the period. State Street Corp boosted its stake in UiPath by 5.3% during the 1st quarter. State Street Corp now owns 5,510,987 shares of the healthcare company’s stock valued at $96,773,000 after purchasing an additional 276,264 shares during the period. Sassicaia Capital Advisers LLC acquired a new stake in UiPath in the 1st quarter valued at approximately $181,000. Finally, Squarepoint Ops LLC grew its holdings in UiPath by 77.7% in the 1st quarter. Squarepoint Ops LLC now owns 566,507 shares of the healthcare company’s stock valued at $9,948,000 after buying an additional 247,661 shares during the last quarter. Hedge funds and other institutional investors own 59.04% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on PATH shares. Barclays increased their price objective on UiPath from $16.00 to $18.00 in a research report on Thursday, September 7th. Bank of America increased their price target on shares of UiPath from $20.00 to $22.00 in a report on Thursday, September 7th. DA Davidson raised their price target on shares of UiPath from $16.00 to $17.00 and gave the stock a “neutral” rating in a research report on Thursday, September 7th. Macquarie upped their price objective on shares of UiPath from $22.00 to $23.00 and gave the company an “outperform” rating in a research report on Thursday, September 7th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $20.00 target price on shares of UiPath in a research note on Thursday, September 7th. Nine research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $19.84.

UiPath Price Performance

UiPath stock opened at $18.16 on Thursday. UiPath Inc. has a 52-week low of $10.40 and a 52-week high of $19.94. The stock has a fifty day moving average price of $16.59 and a two-hundred day moving average price of $16.21. The firm has a market capitalization of $10.19 billion, a P/E ratio of -56.75 and a beta of 0.69.

UiPath (NYSE:PATH) last released its quarterly earnings results on Wednesday, September 6th. The healthcare company reported $0.09 EPS for the quarter, beating analysts’ consensus estimates of $0.04 by $0.05. UiPath had a negative net margin of 15.47% and a negative return on equity of 7.56%. The firm had revenue of $287.31 million for the quarter, compared to analyst estimates of $281.48 million. During the same period in the previous year, the business earned ($0.18) earnings per share. The company’s revenue for the quarter was up 18.6% compared to the same quarter last year. On average, equities research analysts predict that UiPath Inc. will post -0.28 EPS for the current fiscal year.

Insider Activity at UiPath

In other news, Director Rich Wong sold 56,549 shares of the stock in a transaction on Tuesday, July 11th. The stock was sold at an average price of $17.97, for a total transaction of $1,016,185.53. Following the sale, the director now owns 879,693 shares in the company, valued at $15,808,083.21. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other UiPath news, Director Rich Wong sold 56,549 shares of the business’s stock in a transaction dated Tuesday, July 11th. The shares were sold at an average price of $17.97, for a total value of $1,016,185.53. Following the completion of the transaction, the director now directly owns 879,693 shares of the company’s stock, valued at $15,808,083.21. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Ashim Gupta sold 40,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $15.52, for a total transaction of $620,800.00. Following the transaction, the chief financial officer now owns 1,344,047 shares in the company, valued at $20,859,609.44. The disclosure for this sale can be found here. Insiders sold 180,000 shares of company stock valued at $3,155,835 in the last three months. Corporate insiders own 31.03% of the company’s stock.

UiPath Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.